184 related articles for article (PubMed ID: 25806156)
1. Chemotherapy of lung cancer: A global perspective of the role of ifosfamide.
Zhou C; Manegold C
Transl Lung Cancer Res; 2012 Mar; 1(1):61-71. PubMed ID: 25806156
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide and docetaxel in non-small cell lung cancer.
Drings P; Büchholz E; Manegold C
Semin Oncol; 1998 Feb; 25(1 Suppl 2):29-37. PubMed ID: 9535209
[TBL] [Abstract][Full Text] [Related]
4. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer.
Mencoboni M; Lerza R; Castello G; Arboscello E; Barsotti BP; Cerruti A; Ballarino P; Botta M; Bogliolo G; Pannacciulli I
Anticancer Res; 1997; 17(4A):2795-8. PubMed ID: 9252717
[TBL] [Abstract][Full Text] [Related]
7. Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study.
Brocato N; Bruno MF; Araujo CE; Cervellino JC; Pirisi C; Temperley G; Sparrow C; Savulsky C; Balbiani LR
Oncology; 1995; 52(1):24-31. PubMed ID: 7800338
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of ifosfamide and cyclophosphamide.
Brade W; Seeber S; Herdrich K
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-9. PubMed ID: 3545522
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide in non-small cell lung cancer: a review.
Eberhardt W; Niederle N
Semin Oncol; 1992 Feb; 19(1 Suppl 1):40-8. PubMed ID: 1329211
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.
Mauer AM; Ansari RH; Hoffman PC; Krauss SA; Taber D; Tembe SA; Gabrys GT; Cotter T; Schumm LP; Szeto L; Vokes EE
Ann Oncol; 2003 May; 14(5):722-8. PubMed ID: 12702526
[TBL] [Abstract][Full Text] [Related]
12. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
[TBL] [Abstract][Full Text] [Related]
14. Combined chemo- and radiosensitivity testing with ifosfamide and ACNU in human lung cancer cell lines.
Wolf M; Maasberg M; Pfab R; Havemann K
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S187-92. PubMed ID: 1665491
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
16. European experience with ifosfamide in non-small cell lung cancer.
Drings P
Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
[TBL] [Abstract][Full Text] [Related]
17. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
Manegold C; Drings P; Pawinski A; Lentz MA; van Glabbeke M; van Zandwijk N; Bachmann P; Schnaars Y; Skacel Z; Zatloukal P; Dolensky J; Jackevicius A; Petruzelka L; Giaccone G
Ann Oncol; 1996 Aug; 7(6):637-9. PubMed ID: 8879380
[TBL] [Abstract][Full Text] [Related]
18. [Ifosfamide combination chemotherapy for advanced gynecologic malignancies].
Li X; Liu L; Wu L
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):330-2. PubMed ID: 11778564
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Saito Y; Kumamoto T; Makino Y; Tamai I; Ogawa C; Terakado H
Jpn J Clin Oncol; 2016 Sep; 46(9):856-61. PubMed ID: 27380806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
